LockdownV1, Main, Exploration, bibRecord, 001B93

Hard Nanomaterials in Time of Viral Pandemics.

Identifieur interne : 001B93 ( Main/Exploration ); précédent : 001B92; suivant : 001B94

Hard Nanomaterials in Time of Viral Pandemics.

Auteurs : Giacomo Reina [France] ; Shiyuan Peng [France] ; Lucas Jacquemin [France] ; Andrés Felipe Andrade [France] ; Alberto Bianco [France]

Source :

ACS nano [ 1936-086X ] ; 2020.

RBID : pubmed:32667191

Descripteurs français

KwdFr :
- Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (physiologie), Betacoronavirus (ultrastructure), Espèces réactives de l'oxygène (usage thérapeutique), Fullerènes (usage thérapeutique), Humains (MeSH), Immunité acquise (MeSH), Immunité innée (MeSH), Infections à coronavirus (thérapie), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Interactions hôte-microbes (effets des médicaments et des substances chimiques), Modèles biologiques (MeSH), Nanoparticules métalliques (usage thérapeutique), Nanostructures (usage thérapeutique), Nanotechnologie (MeSH), Pandémies (MeSH), Pneumopathie virale (thérapie), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Pénétration virale (effets des médicaments et des substances chimiques), Systèmes de délivrance de médicaments (MeSH).
MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus, Interactions hôte-microbes, Pénétration virale.
- physiologie : Betacoronavirus.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Betacoronavirus, Espèces réactives de l'oxygène, Fullerènes, Nanoparticules métalliques, Nanostructures.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Immunité acquise, Immunité innée, Modèles biologiques, Nanotechnologie, Pandémies, Systèmes de délivrance de médicaments.

English descriptors

KwdEn :
- Adaptive Immunity (MeSH), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (physiology), Betacoronavirus (ultrastructure), COVID-19 (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Drug Delivery Systems (MeSH), Fullerenes (therapeutic use), Host Microbial Interactions (drug effects), Humans (MeSH), Immunity, Innate (MeSH), Metal Nanoparticles (therapeutic use), Models, Biological (MeSH), Nanostructures (therapeutic use), Nanotechnology (MeSH), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Reactive Oxygen Species (therapeutic use), SARS-CoV-2 (MeSH), Virus Internalization (drug effects).
MESH :
- chemical , therapeutic use : Antiviral Agents, Fullerenes, Reactive Oxygen Species.
- drug effects : Betacoronavirus, Host Microbial Interactions, Virus Internalization.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus.
- therapeutic use : Metal Nanoparticles, Nanostructures.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- ultrastructure : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adaptive Immunity, COVID-19, Drug Delivery Systems, Humans, Immunity, Innate, Models, Biological, Nanotechnology, Pandemics, SARS-CoV-2.

Abstract

The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the spread of several viral pandemics such as H2N2 and H3N3 flu, HIV, and SARS, while MERS and Ebola viruses are considered still in a prepandemic phase. Hard nanomaterials (HNMs) have been recently used as antimicrobial agents, potentially being next-generation drugs to fight viral infections. HNMs can block infection at early (disinfection, entrance inhibition) and middle (inside the host cells) stages and are also able to mitigate the immune response. This review is focused on the application of HNMs as antiviral agents. In particular, mechanisms of actions, biological outputs, and limitations for each HNM will be systematically presented and analyzed from a material chemistry point-of-view. The antiviral activity will be discussed in the context of the different pandemic viruses. We acknowledge that HNM antiviral research is still at its early stage, however, we believe that this field will rapidly blossom in the next period.

DOI: 10.1021/acsnano.0c04117
PubMed: 32667191
PubMed Central: PMC7376974

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 002048
to stream Main, to step Curation: 002048

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hard Nanomaterials in Time of Viral Pandemics.</title>
<author><name sortKey="Reina, Giacomo" sort="Reina, Giacomo" uniqKey="Reina G" first="Giacomo" last="Reina">Giacomo Reina</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peng, Shiyuan" sort="Peng, Shiyuan" uniqKey="Peng S" first="Shiyuan" last="Peng">Shiyuan Peng</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacquemin, Lucas" sort="Jacquemin, Lucas" uniqKey="Jacquemin L" first="Lucas" last="Jacquemin">Lucas Jacquemin</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andrade, Andres Felipe" sort="Andrade, Andres Felipe" uniqKey="Andrade A" first="Andrés Felipe" last="Andrade">Andrés Felipe Andrade</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bianco, Alberto" sort="Bianco, Alberto" uniqKey="Bianco A" first="Alberto" last="Bianco">Alberto Bianco</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32667191</idno>
<idno type="pmid">32667191</idno>
<idno type="doi">10.1021/acsnano.0c04117</idno>
<idno type="pmc">PMC7376974</idno>
<idno type="wicri:Area/Main/Corpus">002048</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">002048</idno>
<idno type="wicri:Area/Main/Curation">002048</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">002048</idno>
<idno type="wicri:Area/Main/Exploration">002048</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Hard Nanomaterials in Time of Viral Pandemics.</title>
<author><name sortKey="Reina, Giacomo" sort="Reina, Giacomo" uniqKey="Reina G" first="Giacomo" last="Reina">Giacomo Reina</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peng, Shiyuan" sort="Peng, Shiyuan" uniqKey="Peng S" first="Shiyuan" last="Peng">Shiyuan Peng</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacquemin, Lucas" sort="Jacquemin, Lucas" uniqKey="Jacquemin L" first="Lucas" last="Jacquemin">Lucas Jacquemin</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Andrade, Andres Felipe" sort="Andrade, Andres Felipe" uniqKey="Andrade A" first="Andrés Felipe" last="Andrade">Andrés Felipe Andrade</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bianco, Alberto" sort="Bianco, Alberto" uniqKey="Bianco A" first="Alberto" last="Bianco">Alberto Bianco</name>
<affiliation wicri:level="3"><nlm:affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg</wicri:regionArea>
<placeName><region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Alsace (région administrative)</region>
<settlement type="city">Strasbourg</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">ACS nano</title>
<idno type="eISSN">1936-086X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive Immunity (MeSH)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (physiology)</term>
<term>Betacoronavirus (ultrastructure)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Drug Delivery Systems (MeSH)</term>
<term>Fullerenes (therapeutic use)</term>
<term>Host Microbial Interactions (drug effects)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Innate (MeSH)</term>
<term>Metal Nanoparticles (therapeutic use)</term>
<term>Models, Biological (MeSH)</term>
<term>Nanostructures (therapeutic use)</term>
<term>Nanotechnology (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Reactive Oxygen Species (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Virus Internalization (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Betacoronavirus (ultrastructure)</term>
<term>Espèces réactives de l'oxygène (usage thérapeutique)</term>
<term>Fullerènes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Immunité acquise (MeSH)</term>
<term>Immunité innée (MeSH)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Interactions hôte-microbes (effets des médicaments et des substances chimiques)</term>
<term>Modèles biologiques (MeSH)</term>
<term>Nanoparticules métalliques (usage thérapeutique)</term>
<term>Nanostructures (usage thérapeutique)</term>
<term>Nanotechnologie (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Pénétration virale (effets des médicaments et des substances chimiques)</term>
<term>Systèmes de délivrance de médicaments (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Fullerenes</term>
<term>Reactive Oxygen Species</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Host Microbial Interactions</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Interactions hôte-microbes</term>
<term>Pénétration virale</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Metal Nanoparticles</term>
<term>Nanostructures</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Betacoronavirus</term>
<term>Espèces réactives de l'oxygène</term>
<term>Fullerènes</term>
<term>Nanoparticules métalliques</term>
<term>Nanostructures</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adaptive Immunity</term>
<term>COVID-19</term>
<term>Drug Delivery Systems</term>
<term>Humans</term>
<term>Immunity, Innate</term>
<term>Models, Biological</term>
<term>Nanotechnology</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Immunité acquise</term>
<term>Immunité innée</term>
<term>Modèles biologiques</term>
<term>Nanotechnologie</term>
<term>Pandémies</term>
<term>Systèmes de délivrance de médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the spread of several viral pandemics such as H2N2 and H3N3 flu, HIV, and SARS, while MERS and Ebola viruses are considered still in a prepandemic phase. Hard nanomaterials (HNMs) have been recently used as antimicrobial agents, potentially being next-generation drugs to fight viral infections. HNMs can block infection at early (disinfection, entrance inhibition) and middle (inside the host cells) stages and are also able to mitigate the immune response. This review is focused on the application of HNMs as antiviral agents. In particular, mechanisms of actions, biological outputs, and limitations for each HNM will be systematically presented and analyzed from a material chemistry point-of-view. The antiviral activity will be discussed in the context of the different pandemic viruses. We acknowledge that HNM antiviral research is still at its early stage, however, we believe that this field will rapidly blossom in the next period.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32667191</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1936-086X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>08</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>ACS nano</Title>
<ISOAbbreviation>ACS Nano</ISOAbbreviation>
</Journal>
<ArticleTitle>Hard Nanomaterials in Time of Viral Pandemics.</ArticleTitle>
<Pagination><MedlinePgn>9364-9388</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/acsnano.0c04117</ELocationID>
<Abstract><AbstractText>The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the spread of several viral pandemics such as H2N2 and H3N3 flu, HIV, and SARS, while MERS and Ebola viruses are considered still in a prepandemic phase. Hard nanomaterials (HNMs) have been recently used as antimicrobial agents, potentially being next-generation drugs to fight viral infections. HNMs can block infection at early (disinfection, entrance inhibition) and middle (inside the host cells) stages and are also able to mitigate the immune response. This review is focused on the application of HNMs as antiviral agents. In particular, mechanisms of actions, biological outputs, and limitations for each HNM will be systematically presented and analyzed from a material chemistry point-of-view. The antiviral activity will be discussed in the context of the different pandemic viruses. We acknowledge that HNM antiviral research is still at its early stage, however, we believe that this field will rapidly blossom in the next period.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reina</LastName>
<ForeName>Giacomo</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000-0002-8147-3162</Identifier>
<AffiliationInfo><Affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peng</LastName>
<ForeName>Shiyuan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jacquemin</LastName>
<ForeName>Lucas</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Andrade</LastName>
<ForeName>Andrés Felipe</ForeName>
<Initials>AF</Initials>
<AffiliationInfo><Affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bianco</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000-0002-1090-296X</Identifier>
<AffiliationInfo><Affiliation>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>ACS Nano</MedlineTA>
<NlmUniqueID>101313589</NlmUniqueID>
<ISSNLinking>1936-0851</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037741">Fullerenes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
<QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037741" MajorTopicYN="N">Fullerenes</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076662" MajorTopicYN="N">Host Microbial Interactions</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D036103" MajorTopicYN="N">Nanotechnology</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antiviral</Keyword>
<Keyword MajorTopicYN="Y">biomaterials</Keyword>
<Keyword MajorTopicYN="Y">immune system</Keyword>
<Keyword MajorTopicYN="Y">nanoparticles</Keyword>
<Keyword MajorTopicYN="Y">phototherapy</Keyword>
<Keyword MajorTopicYN="Y">surface chemistry</Keyword>
<Keyword MajorTopicYN="Y">vaccine</Keyword>
<Keyword MajorTopicYN="Y">virucidal</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32667191</ArticleId>
<ArticleId IdType="doi">10.1021/acsnano.0c04117</ArticleId>
<ArticleId IdType="pmc">PMC7376974</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol Methods. 2004 Sep 15;120(2):161-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15288958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Aug 12;9(8):e104113</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25117537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanotoxicology. 2017 Sep;11(7):936-951</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28958187</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2017 Nov 4;493(1):176-181</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28917841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2005 Aug 1;15(15):3615-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15978810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2016 Sep 23;60(10):5731-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27431232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Physiol. 2019 Aug;234(8):12530-12536</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30633361</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioconjug Chem. 2017 Apr 19;28(4):1115-1122</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28177606</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Sep 18;8(9):e70225</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24058438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1986 Oct;24(4):527-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3021808</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Macromol Biosci. 2017 Jun;17(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28296132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2015 Sep 30;7(38):21571-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26370151</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2017 May 2;235:33-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28390972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Theranostics. 2020 Jan 1;10(3):1319-1331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31938067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2018 Sep 26;13:5787-5797</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30310281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomacromolecules. 2013 Feb 11;14(2):431-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23281578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Free Radic Biol Med. 1996;21(5):641-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8891667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Immunol. 2020 Jan;64(1):33-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31692019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomaterials. 2014 Apr;35(13):4195-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24524838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanoscale. 2016 Feb 7;8(5):3040-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26781043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Asian J. 2014 Jun;9(6):1436-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24678063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2017 Mar;241:52-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28040515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Colloid Interface Sci. 2014 Feb;204:15-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24406050</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine. 2017 Jan;13(1):173-182</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27593489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:753-759</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30678964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Colloid Interface Sci. 2019 Apr 15;542:198-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30739009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2007 Feb 9;282(6):4202-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17150970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanosci Nanotechnol. 2012 Mar;12(3):2169-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22755034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Saudi Med J. 2007 Sep;28(9):1418-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17768472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chemistry. 2016 Feb 24;22(9):2987-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26875938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2003 Dec 15;13(24):4437-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14643341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanobiotechnology. 2010 Aug 18;8:19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20718972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Mater. 2013 Nov 6;25(41):5928-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23963730</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2003 Nov-Dec;38(11-12):913-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14642323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1997 Apr;41(4):812-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9087495</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomed Nanotechnol. 2013 Sep;9(9):1624-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23980510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomaterials (Basel). 2019 May 13;9(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31086043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Med Res. 2020 Jul;51(5):384-387</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32402576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2017 May;141:62-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28161578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioconjug Chem. 2009 Aug 19;20(8):1497-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21141805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanoscale. 2019 Aug 29;11(34):15804-15809</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31433428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>RSC Adv. 2018;8(73):41692-41698</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31543960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1596</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31650709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Org Biomol Chem. 2007 Sep 7;5(17):2783-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17700846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanobiotechnology. 2005 Jun 29;3:6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15987516</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanotechnology. 2010 May 14;21(19):195101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20400818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2019 Aug 08;11(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31398832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Environ Microbiol. 2007 Apr;73(8):2748-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17259354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Chem Soc. 2019 Sep 25;141(38):15403-15412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31469952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Rev Microbiol. 2016;42(1):46-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24754250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Nano. 2018 Feb 27;12(2):1188-1202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29357226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanobiotechnology. 2017 Oct 5;15(1):69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28982373</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2017 Mar 31;7(1):519</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28364126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mater Sci Eng C Mater Biol Appl. 2020 Jul;112:110924</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409074</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2005 Feb 15;15(4):1107-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15686922</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Commun (Camb). 2011 Aug 7;47(29):8298-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21666897</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2015 Jun;118:29-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25796971</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2008;153(8):1467-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18592130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Pharm. 2007 Nov-Dec;4(6):807-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17999464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Small. 2010 Dec 20;6(24):2900-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21104827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanobiotechnology. 2020 Mar 24;18(1):54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32209114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2008;13(2):253-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18505176</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2019 Mar 20;10:500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30949169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2020 Feb 14;11:222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32117324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanobiotechnology. 2011 Sep 18;9:38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21923937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2020 Jan;275:113688</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31271792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine. 2019 Feb;16:138-148</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30594660</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Small. 2020 Apr;16(13):e1906206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32077621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Nano. 2015 Jan 27;9(1):663-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25494677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Small. 2014 Nov;10(22):4505-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25238620</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2018 Nov 15;19(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30445702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1543-1558</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31007088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Mater. 2018 Feb;17(2):195-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29251725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2004 May;53(5):759-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15028666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2014 Sep 22;190:1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24979044</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2016 Jun 1;196(11):4566-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27183601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Chem Soc. 2008 Jun 4;130(22):6896-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18473457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biotechnol. 2001 Sep;19(1):79-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11697222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2011 Dec;178(1-2):137-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21945220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomed Sci. 2019 Sep 10;26(1):70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31500628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2013 Dec 11;5(23):12488-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24180242</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19799-19807</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31099550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Small. 2010 May 7;6(9):1044-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20394070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2013;8:4303-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24235828</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2018 Apr 03;13:2005-2016</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29662313</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 2012;509:21-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22568899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genet Mol Res. 2014 Mar 19;13(3):7022-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24682984</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine. 2016 Nov;12(8):2299-2310</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27381068</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Microbiol Biotechnol. 2019 Jan;103(1):437-447</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30402771</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanoscale. 2011 Oct 5;3(10):4035-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21897967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanoscale Res Lett. 2016 Dec;11(1):449</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27709563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Healthc Mater. 2016 Nov;5(22):2922-2930</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27581958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1021-1026</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32285293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biosci Bioeng. 2012 May;113(5):580-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22227118</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Colloids Surf B Biointerfaces. 2014 Nov 1;123:264-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25300473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Chem. 2016 Jan;8(1):50-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27055288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nanobiotechnology. 2010 Jan 20;8:1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20145735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2017 Aug 09;12:5733-5743</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28848350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Jun 25;5(6):e11295</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20592763</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2013 Nov;193(2):470-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23886562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Physiol Behav. 2017 Jul 1;176:139-148</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28363838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Dermatol. 2007 Apr;46(4):427-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17442091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2012 Dec;96(3):363-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23047013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Colloids Surf B Biointerfaces. 2018 Mar 1;163:55-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29277018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Environ Microbiol. 2012 Feb;78(4):951-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22156433</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 2000;69:531-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10966468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2016 Aug 1;103:76-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26952542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Adv. 2020 Jan 29;6(5):eaax9318</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32064341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Mar;89(5):2462-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25428874</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 16;382(16):1564-1567</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32182409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2016 Apr 13;8(14):9004-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27015417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Soc Rev. 2017 Jul 31;46(15):4400-4416</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28722038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2012;7:5007-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23049252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2019 Jul 01;11(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31266258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Commun (Camb). 2013 Sep 25;49(74):8241-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23926597</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mater Chem B. 2017 Aug 28;5(32):6566-6571</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32264418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol Methods. 2015 Sep 15;222:150-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26116793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Nanomedicine. 2014;9:77-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24379667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mater Sci Eng C Mater Biol Appl. 2018 Aug 1;89:413-421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29752114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carbohydr Polym. 2019 Dec 15;226:115261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31582052</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nanomedicine (Lond). 2018 Nov;13(21):2675-2690</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30346253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18590-18596</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31451630</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2014 Jan 22;6(2):1228-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24364493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Molecules. 2016 Jun 27;21(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27355939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Appl Mater Interfaces. 2016 Sep 21;8(37):24385-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27588566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110052</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31546360</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Nanotechnol. 2020 Mar;15(3):164-166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32157238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2006 Jun;36(6):1364-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16703568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>P T. 2017 Dec;42(12):742-755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29234213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Trace Elem Med Biol. 2015 Oct;32:30-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26302909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Environ Microbiol. 1994 Jul;60(7):2377-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8074518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2010 Jul 22;6(7):e1000943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20661480</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Alsace (région administrative)</li>
<li>Grand Est</li>
</region>
<settlement><li>Strasbourg</li>
</settlement>
</list>
<tree><country name="France"><region name="Grand Est"><name sortKey="Reina, Giacomo" sort="Reina, Giacomo" uniqKey="Reina G" first="Giacomo" last="Reina">Giacomo Reina</name>
</region>
<name sortKey="Andrade, Andres Felipe" sort="Andrade, Andres Felipe" uniqKey="Andrade A" first="Andrés Felipe" last="Andrade">Andrés Felipe Andrade</name>
<name sortKey="Bianco, Alberto" sort="Bianco, Alberto" uniqKey="Bianco A" first="Alberto" last="Bianco">Alberto Bianco</name>
<name sortKey="Jacquemin, Lucas" sort="Jacquemin, Lucas" uniqKey="Jacquemin L" first="Lucas" last="Jacquemin">Lucas Jacquemin</name>
<name sortKey="Peng, Shiyuan" sort="Peng, Shiyuan" uniqKey="Peng S" first="Shiyuan" last="Peng">Shiyuan Peng</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/LockdownV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B93 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B93 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    LockdownV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32667191
   |texte=   Hard Nanomaterials in Time of Viral Pandemics.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32667191" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LockdownV1

This area was generated with Dilib version V0.6.38.
Data generation: Sun Jan 31 08:28:27 2021. Site generation: Sun Jan 31 08:33:49 2021

	Serveur d'exploration sur le confinement (PubMed)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le confinement (PubMed)

Hard Nanomaterials in Time of Viral Pandemics.

Hard Nanomaterials in Time of Viral Pandemics.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki